Scleroderma Therapeutics Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021-2028)

Scleroderma is a rare autoimmune disease that affects the connective tissues of the body. It causes hardening and thickening of the skin and can also affect internal organs such as the lungs, heart, and kidneys. The exact cause of scleroderma is unknown, and there is currently no cure for the disease. However, there are several treatments available that can help manage the symptoms and slow down the progression of the disease.

Overview

The global scleroderma therapeutics market is expected to grow at a steady rate over the forecast period (2021-2028). The increasing prevalence of scleroderma, along with the growing awareness about the disease, is expected to drive the market growth. According to the Scleroderma Foundation, approximately 300,000 people in the United States have scleroderma, and the disease affects women more than men. The foundation also estimates that the disease affects approximately 2.5 million people worldwide.

The market for scleroderma therapeutics is segmented by drug class, route of administration, and geography. The drug classes include immunosuppressants, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and others. The route of administration includes oral, injectable, and topical.

Key Players in the Scleroderma Therapeutics Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021-2028)

The key players in the scleroderma therapeutics market include Actelion Pharmaceuticals Ltd., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Pfizer Inc., Sanofi S.A., and United Therapeutics Corporation.

These companies are focusing on developing new and innovative treatments for scleroderma. For example, Actelion Pharmaceuticals Ltd. has developed a drug called Tracleer, which is an endothelin receptor antagonist that is used to treat pulmonary arterial hypertension (PAH) associated with scleroderma. United Therapeutics Corporation has developed a drug called Orenitram, which is a prostacyclin analogue that is used to treat PAH associated with scleroderma.

Market Challenges

One of the major challenges facing the scleroderma therapeutics market is the high cost of treatment. Many of the drugs used to treat scleroderma are expensive, and this can be a barrier to access for many patients. In addition, there is a lack of awareness about the disease, which can lead to delays in diagnosis and treatment.

Another challenge facing the market is the limited number of treatment options available. While there are several drugs available to manage the symptoms of scleroderma, there is currently no cure for the disease. This highlights the need for continued research and development of new treatments for scleroderma.

Market Opportunities

Despite the challenges facing the scleroderma therapeutics market, there are several opportunities for growth. One of the key opportunities is the increasing prevalence of scleroderma, which is expected to drive demand for new and innovative treatments. In addition, there is a growing focus on personalized medicine, which could lead to the development of more targeted treatments for scleroderma.

Another opportunity for growth is the increasing use of combination therapies. Many of the drugs used to treat scleroderma are used in combination with other drugs to achieve better outcomes. This could lead to the development of new combination therapies that are more effective at managing the symptoms of scleroderma.

Future of the Scleroderma Therapeutics Market

The future of the scleroderma therapeutics market looks promising, with several new treatments in development. For example, Corbus Pharmaceuticals Holdings, Inc. is developing a drug called lenabasum, which is a synthetic oral endocannabinoid-mimetic drug that is being studied for the treatment of systemic sclerosis and dermatomyositis.

In addition, there is a growing focus on precision medicine, which could lead to the development of more targeted treatments for scleroderma. Precision medicine involves using genetic and other information to develop personalized treatment plans for patients. This could lead to more effective treatments with fewer side effects.

Conclusion

The scleroderma therapeutics market is expected to grow at a steady rate over the forecast period (2021-2028). The increasing prevalence of scleroderma, along with the growing awareness about the disease, is expected to drive the market growth. While there are several challenges facing the market, there are also several opportunities for growth, including the increasing use of combination therapies and the growing focus on personalized medicine. The future of the scleroderma therapeutics market looks promising, with several new treatments in development.